MA51679A - Composés destinés au traitement de troubles dépendant de la kinase - Google Patents
Composés destinés au traitement de troubles dépendant de la kinaseInfo
- Publication number
- MA51679A MA51679A MA051679A MA51679A MA51679A MA 51679 A MA51679 A MA 51679A MA 051679 A MA051679 A MA 051679A MA 51679 A MA51679 A MA 51679A MA 51679 A MA51679 A MA 51679A
- Authority
- MA
- Morocco
- Prior art keywords
- kinase
- treatment
- compounds intended
- dependent disorders
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622702P | 2018-01-26 | 2018-01-26 | |
| US201862622626P | 2018-01-26 | 2018-01-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51679A true MA51679A (fr) | 2020-12-02 |
Family
ID=65685938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051679A MA51679A (fr) | 2018-01-26 | 2019-01-25 | Composés destinés au traitement de troubles dépendant de la kinase |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11673897B2 (fr) |
| EP (1) | EP3743417A1 (fr) |
| JP (1) | JP7480048B2 (fr) |
| CN (1) | CN111936487B (fr) |
| AU (1) | AU2019212800B2 (fr) |
| CA (1) | CA3088198A1 (fr) |
| MA (1) | MA51679A (fr) |
| WO (1) | WO2019148043A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117402114A (zh) * | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| CN115461328B (zh) | 2020-04-30 | 2025-11-07 | 埃克塞里艾克西斯公司 | 用于制备激酶抑制剂的方法 |
| TW202241862A (zh) * | 2021-02-01 | 2022-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 二甲醯胺類化合物、其製備方法及其在醫藥上的應用 |
| MX2023009560A (es) * | 2021-02-17 | 2023-10-25 | Springworks Therapeutics Inc | Solidos cristalinos del inhibidor de mek n-((r)-2,3-dihidroxipropo xi)-3,4-difluoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida y sus usos. |
| WO2026074526A1 (fr) * | 2024-10-04 | 2026-04-09 | Hetero Labs Limited | Composés 1,2-dicarboxamide utilisés en tant qu'inhibiteurs de kinase |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508537D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| EA001595B1 (ru) | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Необратимые ингибиторы тирозинкиназ |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| AU9598601A (en) | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| US8466143B2 (en) * | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Azepine derivatives as pharmaceutical agents |
| EP2210607B1 (fr) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(méthyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phényl]-N'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide pour le traitement du cancer |
| CA2604238C (fr) | 2005-04-15 | 2015-07-07 | Neogenix Oncology, Inc. | Anticorps monoclonaux recombines et antigenes correspondants contre les cancers du colon et du pancreas |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| AU2006309551B2 (en) | 2005-11-07 | 2012-04-19 | Eisai R & D Management Co., Ltd. | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
| WO2007103308A2 (fr) * | 2006-03-07 | 2007-09-13 | Array Biopharma Inc. | Dérivés hétérobicycliques de pyrazole et méthodes d'utilisation |
| PL2101759T3 (pl) * | 2006-12-14 | 2019-05-31 | Exelixis Inc | Sposoby stosowania inhibitorów MEK |
| WO2009017838A2 (fr) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinaisons d'inhibiteurs jak-2 et d'autres agents |
| ES2599458T3 (es) | 2008-10-14 | 2017-02-01 | Sunshine Lake Pharma Co., Ltd. | Compuestos y métodos de uso |
| JP5444365B2 (ja) * | 2008-10-29 | 2014-03-19 | デシフェラ ファーマシューティカルズ，エルエルシー | 抗癌活性および抗増殖活性を示すシクロプロパンアミドおよび類似物質 |
| EP2213686A1 (fr) | 2009-01-28 | 2010-08-04 | Externautics S.p.A. | Marqueurs de tumeur et procédés d'utilisation correspondants |
| EP2214019A1 (fr) | 2009-01-28 | 2010-08-04 | Externautics S.p.A. | Marqueurs de tumeurs et leurs utilisations |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| EP2494351B1 (fr) | 2009-10-26 | 2016-06-08 | Externautics S.p.A. | Marqueurs de tumeurs du rectum et du côlon, et leurs méthodes d'utilisation |
| US8921058B2 (en) | 2009-10-26 | 2014-12-30 | Externautics Spa | Prostate tumor markers and methods of use thereof |
| WO2011051277A1 (fr) | 2009-10-26 | 2011-05-05 | Externautics S.P.A. | Marqueurs de tumeurs du sein et leurs méthodes d'utilisation |
| US10288617B2 (en) | 2009-10-26 | 2019-05-14 | Externautics Spa | Ovary tumor markers and methods of use thereof |
| WO2011051278A1 (fr) | 2009-10-26 | 2011-05-05 | Externautics S.P.A. | Marqueurs de tumeurs du poumon et leurs méthodes d'utilisation |
| US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
| EP2383578A1 (fr) | 2010-04-30 | 2011-11-02 | Externautics S.p.A. | Marqueur de tumeur et procédés d'utilisation correspondants |
| ES2598530T3 (es) * | 2010-07-14 | 2017-01-27 | Betta Pharmaceuticals Co., Ltd. | Nuevos derivados heterocíclicos condensados útiles como inhibidores de la tirosina quinasa c-Met |
| US8664244B2 (en) | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| CN102093421B (zh) | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| EP3008086A2 (fr) | 2013-06-14 | 2016-04-20 | Externautics S.p.A. | Marqueur de tumeur, anticorps monoclonaux et procédés pour les utiliser |
| IL292510A (en) | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| UA121655C2 (uk) * | 2014-04-25 | 2020-07-10 | Екселіксіс, Інк. | Спосіб лікування аденокарциноми легень |
| CN104817497B (zh) | 2015-03-20 | 2017-03-08 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| CN106279147A (zh) * | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
| US20170342033A1 (en) | 2015-06-29 | 2017-11-30 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
| US20180009758A1 (en) | 2015-06-29 | 2018-01-11 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
| CN105797123A (zh) | 2016-05-18 | 2016-07-27 | 王超 | 一种治疗不孕不育的中药组合物 |
| CN106400155A (zh) | 2016-08-31 | 2017-02-15 | 飞佛特种纺织品（宁波）有限公司 | 一种防老化阳光面料 |
| CN107235896B (zh) | 2016-09-13 | 2019-11-05 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| CN110049969A (zh) | 2017-02-07 | 2019-07-23 | 恩瑞生物医药科技（上海）有限公司 | 喹啉类化合物、其制备方法及其医药用途 |
| WO2018153293A1 (fr) * | 2017-02-27 | 2018-08-30 | 北京赛特明强医药科技有限公司 | Dioxanoquinazoline, composé de type dioxanoquinazoline, procédé de préparation et utilisation associés |
| SG11202005719UA (en) | 2017-12-20 | 2020-07-29 | Angex Pharmaceutical Inc | Carbamate and urea compounds as multikinase inhibitors |
| CR20250117A (es) | 2018-01-26 | 2025-05-09 | Exelixis Inc | COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-0355) |
| CN117402114A (zh) | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
-
2019
- 2019-01-25 CA CA3088198A patent/CA3088198A1/fr active Pending
- 2019-01-25 WO PCT/US2019/015296 patent/WO2019148043A1/fr not_active Ceased
- 2019-01-25 EP EP19709144.0A patent/EP3743417A1/fr active Pending
- 2019-01-25 JP JP2020540745A patent/JP7480048B2/ja active Active
- 2019-01-25 US US16/964,274 patent/US11673897B2/en active Active
- 2019-01-25 MA MA051679A patent/MA51679A/fr unknown
- 2019-01-25 AU AU2019212800A patent/AU2019212800B2/en active Active
- 2019-01-25 CN CN201980021651.XA patent/CN111936487B/zh active Active
-
2023
- 2023-04-07 US US18/132,124 patent/US20240150371A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019148043A1 (fr) | 2019-08-01 |
| AU2019212800B2 (en) | 2024-05-23 |
| CN111936487B (zh) | 2024-07-09 |
| US11673897B2 (en) | 2023-06-13 |
| JP7480048B2 (ja) | 2024-05-09 |
| CN111936487A (zh) | 2020-11-13 |
| JP2021511357A (ja) | 2021-05-06 |
| EP3743417A1 (fr) | 2020-12-02 |
| US20210032263A1 (en) | 2021-02-04 |
| CA3088198A1 (fr) | 2019-08-01 |
| AU2019212800A1 (en) | 2020-08-20 |
| US20240150371A1 (en) | 2024-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51673A (fr) | Composés destinés au traitement de troubles dépendant de la kinase | |
| EP3411380A4 (fr) | Composés destinés au traitement de troubles ou de maladies oculaires | |
| MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
| EP3448389A4 (fr) | Composés de quinazoline et d'indole destinés au traitement de troubles médicaux | |
| EP3704108A4 (fr) | Composés et compositions pour le traitement de troubles hématologiques | |
| MA51679A (fr) | Composés destinés au traitement de troubles dépendant de la kinase | |
| MA53664A (fr) | Composés destinés au traitement de certaines leucémies | |
| MA52778A (fr) | Méthodes de traitement de troubles associés au récepteur s1p1 | |
| EP3352749A4 (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| MA44875A (fr) | Compositions pour le traitement de troubles acido-basiques | |
| MA56114A (fr) | Composés pour le traitement de troubles dépendant de la kinase | |
| MA52761A (fr) | Schéma posologique destiné au traitement de troubles liés à la pi3k | |
| EP3805216A4 (fr) | Composés pour le traitement ou la prévention de maladies hépatiques | |
| MA49140A (fr) | Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques | |
| EP3593803A4 (fr) | Composés destinés au traitement de maladies causées par l'accumulation d'oxalate | |
| MA47207A (fr) | Composés utiles pour le traitement de troubles du tractus digestif | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| MA46099A (fr) | Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial | |
| EP3877382A4 (fr) | Nouveaux composés pour le traitement de maladies respiratoires | |
| EP3373931A4 (fr) | Composés hétérocycliques pour le traitement de maladies | |
| MA53817A (fr) | Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv | |
| MA53636A (fr) | Agent de traitement de troubles dermatologiques | |
| MA50495A (fr) | Composés bicycliques à fusion 5,6 et compositions pour le traitement de maladies parasitaires | |
| EP3630986A4 (fr) | Thérapie génique destinée au traitement de troubles des peroxysomes | |
| MA56501A (fr) | Composés destinés au traitement de troubles neuromusculaires |